Literature DB >> 8675649

Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity.

A D Baron1, J S Zhu, J H Zhu, H Weldon, L Maianu, W T Garvey.   

Abstract

Glucosamine (Glmn), a product of glucose metabolism via the hexosamine pathway, causes insulin resistance in isolated adipocytes by impairing insulin-induced GLUT 4 glucose transporter translocation to the plasma membrane. We hypothesized that Glmn causes insulin resistance in vivo by a similar mechanism in skeletal muscle. We performed euglycemic hyperinsulinemic clamps (12 mU/kg/min + 3H-3-glucose) in awake male Sprague-Dawley rats with and without Glmn infusion at rates ranging from 0.1 to 6.5 mg/kg/min. After 4h of euglycemic clamping, hindquarter muscles were quick-frozen and homogenized, and membranes were subfractionated by differential centrifugation and separated on a discontinuous sucrose gradient (25, 30, and 35% sucrose). Membrane proteins were solubilized and immunoblotted for GLUT 4. With Glmn, glucose uptake (GU) was maximally reduced by 33 +/- 1%, P < 0.001. The apparent Glmn dose to reduce maximal GU by 50% was 0.1 mg/kg/min or 1/70th the rate of GU on a molar basis. Control galactosamine and mannosamine infusions had no effect on GU. Relative to baseline, insulin caused a 2.6-fold increase in GLUT 4 in the 25% membrane fraction (f), P < 0.01, and a 40% reduction in the 35%f, P < 0.05, but had no effect on GLUT 4 in the 30% f, P= NS. Addition of Glmn to insulin caused a 41% reduction of GLUT 4 in the 25%f, P < 0.05, a 29% fall in the 30%f, and prevented the reduction of GLUT 4 in the 35% f. The 30%f membranes were subjected to a second separation with a 27 and 30% sucrose gradient. Insulin mobilized GLUT 4 away from the 30%f, P < 0.05, but not the 27% f. In contrast, Glmn reduced GLUT 4 in the 27%f, P < 0.05, but not the 30%f. Thus Glmn appears to alter translocation of an insulin-insensitive GLUT 4 pool. Coinfusion of Glmn did not alter enrichment of the sarcolemmal markers 5'-nucleotidase, Na+/K+ATPase, and phospholemman in either 25, 30, or 35% f. Thus Glmn completely blocked movement of Glut 4 induced by insulin. Glmn is a potent inducer of insulin resistance in vivo by causing (at least in part) a defect intrinsic to GLUT 4 translocation and/or trafficking. These data support a potential role for Glmn to cause glucose-induced insulin resistance (glucose toxicity).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8675649      PMCID: PMC185989          DOI: 10.1172/JCI118349

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Cellular insulin action and insulin resistance.

Authors:  W T Garvey; M J Birnbaum
Journal:  Baillieres Clin Endocrinol Metab       Date:  1993-10

5.  Assay of Na,K-ATPase in plasma membrane preparations: increasing the permeability of membrane vesicles using sodium dodecyl sulfate buffered with bovine serum albumin.

Authors:  B Forbush
Journal:  Anal Biochem       Date:  1983-01       Impact factor: 3.365

6.  Effect of insulin therapy on insulin resistance in type II diabetic subjects. Evidence for heterogeneity.

Authors:  H Ginsberg; E J Rayfield
Journal:  Diabetes       Date:  1981-09       Impact factor: 9.461

7.  The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects.

Authors:  O G Kolterman; R S Gray; G Shapiro; J A Scarlett; J Griffin; J M Olefsky
Journal:  Diabetes       Date:  1984-04       Impact factor: 9.461

8.  Lack of in vivo insulin resistance in controlled insulin-dependent, type I, diabetic patients.

Authors:  R R Revers; O G Kolterman; J A Scarlett; R S Gray; J M Olefsky
Journal:  J Clin Endocrinol Metab       Date:  1984-02       Impact factor: 5.958

9.  Insulin treatment reverses the postreceptor defect in adipocyte 3-O-methylglucose transport in type II diabetes mellitus.

Authors:  J A Scarlett; O G Kolterman; T P Ciaraldi; M Kao; J M Olefsky
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

10.  Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus.

Authors:  M S Greenfield; L Doberne; M Rosenthal; B Schulz; A Widstrom; G M Reaven
Journal:  Diabetes       Date:  1982-04       Impact factor: 9.461

View more
  45 in total

Review 1.  Plasma leptin and exercise: recent findings.

Authors:  Matthew W Hulver; Joseph A Houmard
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial.

Authors:  Nicola Giordano; Antonella Fioravanti; Panagiotis Papakostas; Antonio Montella; Giorgio Giorgi; Ranuccio Nuti
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

3.  The hexosamine biosynthesis pathway is essential for pancreatic beta cell development.

Authors:  Gaëlle Filhoulaud; Ghislaine Guillemain; Raphaël Scharfmann
Journal:  J Biol Chem       Date:  2009-07-07       Impact factor: 5.157

4.  Possible role for gp160 in constitutive but not insulin-stimulated GLUT4 trafficking: dissociation of gp160 and GLUT4 localization.

Authors:  A Filippis; S Clark; J Proietto
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

5.  Role of the glucosamine pathway in fat-induced insulin resistance.

Authors:  M Hawkins; N Barzilai; R Liu; M Hu; W Chen; L Rossetti
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

Review 6.  Type 2 diabetes mellitus and osteoarthritis.

Authors:  Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen
Journal:  Semin Arthritis Rheum       Date:  2019-01-11       Impact factor: 5.532

7.  Effect of +36T>C in intron 1 on the glutamine: fructose-6-phosphate amidotransferase 1 gene and its contribution to type 2 diabetes in different populations.

Authors:  Kiyoshi Kunika; Toshihito Tanahashi; Eiji Kudo; Noriko Mizusawa; Eiichiro Ichiishi; Naoto Nakamura; Toshikazu Yoshikawa; Takashi Yamaoka; Hiroaki Yasumo; Kazue Tsugawa; Maki Moritani; Hiroshi Inoue; Mitsuo Itakura
Journal:  J Hum Genet       Date:  2006-09-26       Impact factor: 3.172

8.  Increased flux through the hexosamine biosynthesis pathway inhibits glucose transport acutely by activation of protein kinase C.

Authors:  A Filippis; S Clark; J Proietto
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

9.  Exploring levels of hexosamine biosynthesis pathway intermediates and protein kinase C isoforms in muscle and fat tissue of Zucker Diabetic Fatty rats.

Authors:  Remko R Bosch; Susan W J Janssen; Paul N Span; André Olthaar; Sjenet E van Emst-de Vries; Peter H G M Willems; Gerard Martens J M; Ad R M M Hermus; C C J Sweep
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

10.  Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia.

Authors:  Donald A McClain; William A Lubas; Robert C Cooksey; Mark Hazel; Glendon J Parker; Dona C Love; John A Hanover
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.